Zeltia links up with Taiho to sell Yondelis in Japan
Spain’s Zeltia says that its PharmaMar has signed a licensing agreement with Taiho Pharmaceutical for its anti-cancer agent Yondelis in Japan.
Read MoreAuthor: Kevin Grogan
Osiris halts Prochymal trial as analysts debate value of therapy
Shares in Osiris Therapeutics have fallen over 21% after the US firm halted a late-stage trial of its Crohn’s disease treatment Prochymal, which it hopes will become the first stem cell therapy to be given full approval.
Read MoreTakeda sets up Canadian unit to push North America growth
In a bid to expand its presence outside Japan, Takeda Pharmaceutical Co is setting up a subsidiary in Canada.
Read MorePharma sector unimpressed with latest US biosimilars proposal
Another bill has been introduced on biosimilars in the USA, this time by a bipartisan group of senators, which would give branded biologics just five years of market exclusivity.
Read MoreElan Corp shares soar on Lundbeck takeover rumour
Shares in Elan Corp have leapt on rumours Denmark’s Lundbeck is planning a takeover bid for the Irish drugmaker, although the likelihood of such a bid is being questioned by some analysts.
Read More- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
